Publications and Presentations Sample Clauses
The "Publications and Presentations" clause governs how parties may disclose information about the agreement or the work performed under it through public communications such as articles, conference talks, or press releases. Typically, this clause requires one party to obtain the other party's consent before publishing or presenting any material that references the project, its results, or confidential information. Its core function is to protect sensitive information and intellectual property, ensuring that disclosures do not compromise competitive advantage or breach confidentiality obligations.
POPULAR SAMPLE Copied 2 times
Publications and Presentations. For purposes of this Agreement, “Scientific Publication” means any scientific publication or medical communication regarding Study results in any form that is intended for disclosure to third parties, including, without limitation, manuscripts, abstracts, posters, slides or other materials used for presentations.
Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining to the Research Program or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) that relate to the Research Program or any Co-Development Program at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party is given up to [***] days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submi...
Publications and Presentations. Jazz and its Affiliates may publish or present, or permit to be published or presented, the design (including clinical design, but excluding any Codiak Platform Know-How) or results of the Development, Manufacture, Commercialization, or other Exploitation of the Collaboration Targets, Licensed Compounds, or Licensed Products (the “Covered Results”). Codiak agrees that, except as required by Applicable Laws, it and its Affiliates shall not publish or present, or permit to be published or presented, the Covered Results without the prior review by and approval of Jazz, which approval shall not be unreasonably withheld, conditioned or delayed; provided, that it shall be deemed reasonable for Jazz to withhold its consent to any request by Codiak to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Jazz or its Affiliates. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed (a) abstracts and manuscripts for scientific journals or conferences that relate to the Covered Results at least [***] prior to intended submission for publication, and (b) presentations at scientific conferences (including information to be presented verbally) that relate to the Covered Results at least [***] prior to its intended presentation. Upon written request from a Party given within such applicable review period, the other Party shall (i) not submit such abstract or manuscript for publication or make such presentation until appropriate patent applications are filed to protect any unpatented Know-How disclosed in such publication or presentation that such Party reasonably believes may be patentable and (ii) remove any Confidential Information of such Party that is disclosed in any such proposed publication or presentation prior to such publication or presentation. Once such abstracts, manuscripts or presentations (or the information contained therein) have been reviewed and, if applicable, modified for publication or presentation pursuant to this Section 9.4, the same abstracts, manuscripts or presentations (and the information contained therein) do not have to be provided again by one Party to the other Party for review for a later submission for publication. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.
Publications and Presentations. Neither Party will publicly present or publish the results of, or scientific information regarding, any activities specific to Collaboration Compounds, Licensed Compounds, or the Licensed Products under this Agreement (each such proposed presentation or publication, a “Publication”) absent the other Party’s prior written consent; provided that following an Opt-Out by a Party, the Continuing Party will have the sole right to publicly present or publish any Publication, without the obligation to obtain the prior written consent of the Opt-Out Party as long as it complies with the other terms of this Section 14.3 (Publications and Presentations) below. Any Publication will be made in a manner consistent with Applicable Law and industry practices and subject to the procedure set forth in this Section 14.3 (Publications and Presentations). In addition, prior to publicly presenting or publishing any Publication, the publishing Party will provide the other Party with drafts of such proposed Publication. If requested by the other Party within [***] following receipt of such proposed Publication (or such shorter period as may be agreed upon by the Parties), the publishing Party will delay any such proposed Publication for a reasonable period (not to exceed [***] after the other Party receives such proposed Publication) to permit the other Party to make filings for patent protection, and the publishing Party will otherwise remove Confidential Information of the other Party (except to the extent comprising Joint Collaboration Know-How related to the publishing Party’s activities with respect to the Licensed Compounds and Licensed Products) that is identified by the other Party in such proposed Publication within such [***] (or shorter, as applicable) period. Each Party agrees to acknowledge the contributions of the other Party and the other Party’s employees, in each case, in accordance with standard academic practice regarding authorship of scientific publication.
Publications and Presentations. The Parties acknowledge that scientific lead-time is a key element of the value of the research and development activities under the Collaboration and further agree that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or disclosure of results of the research or development activities hereunder. At least thirty (30) days prior to submission of any material related to the research or development activities hereunder for publication or presentation, the submitting Party will provide to the receiving Party a draft of such material for its review and comment. The receiving Party will provide any comments to the submitting Party within twenty (20) days of receipt of such materials alerting the submitting Party to the presence of the receiving Party’s Confidential Information or patentable subject matter that requires protection and in each case, specifically identifying such information (“Notice of Objection”). Each Party will reasonably review proposed publications and presentations submitted by the other Party as promptly as possible and will not unreasonably withhold its consent to such publications or presentations that have been submitted for review with less than the required notice period.
5.3.1 In the event the receiving party makes such Notice of Objection, the submitting party shall refrain from disclosing the material until the receiving Party’s Confidential Information, as identified in the Notice of Objection, is removed. Once the receiving Party’s Confidential Information has been removed, the Notice of Objection will be deemed withdrawn and the submitting party shall not be restricted from publishing the material, provided that any objection based on patentable subject matter contained in the material has also been addressed in accordance with the terms of section 5.3.2.
5.3.2 If the Notice of Objection identifies patentable subject matter then the submitting Party will withhold the material from submission for publication or presentation and the Parties shall work together in good faith and, as quickly as possible after receipt of the Notice of Objection, to file patents and take all necessary measures to establish and preserve proprietary rights that may be contained in the material being submitted for publication or presentation as identified in the Notice of Objection. Once the Parties have taken such steps to protect the patentable subject matter, the Notice of Obje...
Publications and Presentations. Please list the journal article publications based on the findings of this work. Please indicate their status (planned, in draft, under review, submitted, in-press, published). Please indicate the conferences to which you have submitted abstracts and their status (i.e. accepted, oral presentation / poster presentation) Please list any invitations for oral presentations where you have or plan to present the findings of this research.
Publications and Presentations. Without Pfizer's written prior approval, Supplier shall not:
a) make any presentation, public announcement, or publication of any kind relating to any and all matters arising out of or in connection with this PO, including this PO itself, or
b) use in any matter whatsoever any trademarks, logos, service marks, trade names, corporate names, proprietary logos, indicia or other business identifiers of any sort of Pfizer.
Publications and Presentations. 4.1 Each Party will have the right to publish or give public presentations of the Common Results (as defined in § 5.1) but shall be subject to the prior written agreement of all of the other Parties. The details and timing of the decision to publish or give a presentation and the extent and content of the publication or presentation shall also be agreed beforehand, in writing between all the Parties (see §§ 4.3 and 4.4). Any other publication or presentation of the Common Results is strictly forbidden to the Parties. For the avoidance of doubt, unless otherwise agreed in writing by the concerned Parties, no publication or presentation of any Party’s Background IP and/or Own Common Results is permitted, directly as indirectly, in any manner whatsoever.
4.2 All publications and presentations on the Common Results shall be made under the joint authorship of the Parties in compliance with the rules of good scientific practice. Furthermore, all publications and presentations shall include that the Research Project, and more generally, this Agreement, is covered by a grant from the ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇- ▇▇▇▇▇ COFUND Programme “InnovaXN” (contract number 847439 with the European Commission). Each submission for publication shall be signed by the Supervisors referred to in § 2.5. Each presentation shall contain written text that acknowledges and mentions the joint authorship and the contribution made by each of the Parties in compliance with the rules of good scientific practice. For the sole need of the present article 4.2, each Party consents to the others, in the terms and conditions hereunder convened, a free and non-exclusive right of exploitation of its name and logo, for the validity period of this Agreement. This right shall cease immediately and automatically in case of termination of this Agreement, whatever the cause or the date. Prior termination against a/several Party(ies) shall however not call into question the survival of this right for the non- concerned Parties, which remains in force, until the agreed contractual term.
4.3 The Party wishing to publish shall notify the other Parties by submitting a copy of the manuscript for review and comment, so as to arrive at least 45 (forty five) calendar days before the due date for submission for publication. The Party wishing to give a presentation shall notify the other Parties by submitting for review and comment a copy of the description of the content of the presentation and a copy of any visual aids to ...
Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of the Research Program to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property (the “Covered Results”) without the prior review by and approval of the other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including, without limitation, information to be presented verbally) that relate to the Covered Results at least [***] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] days [***] from the date of such written request to seek appropriate patent protection for any Covered Rights in such publication or presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.
Publications and Presentations. The publication and presentation of Study Data and Sample Data, including provisions regarding the Confidential Information of a Party contained in such a disclosure, is governed by Section 8.2.